Cardiac Magnetic Resonance Imaging used for Evaluation of Adipose-Derived Stromal Cell Therapy in Patients with Chronic Ischemic Heart Disease
Open Access
- 8 November 2019
- journal article
- research article
- Published by SAGE Publications in Cell Transplantation
- Vol. 28 (12), 1700-1708
- https://doi.org/10.1177/0963689719883592
Abstract
Adipose-derived stromal cell (ASC) therapy is currently investigated as a new treatment option for patients with ischemic heart disease (IHD). The aim of this study was to evaluate the effect of ASC therapy in patients with chronic IHD measuring myocardial perfusion and cardiac function using cardiac magnetic resonance imaging (CMRI). Patients were included in MyStromalCell trial, a phase II, randomized, double-blinded, placebo-controlled study investigated the effect of ASCs in patients with chronic IHD with preserved left ventricular ejection fraction (LVEF). In total, 41 of 60 patients underwent cine, late enhancement, rest and stress imaging with CMRI. There was a non-significant difference between stress and rest values in maximal signal intensity, a measure of myocardial perfusion, from baseline to follow-up comparing placebo with ASC group (–52.52 ± 88.61 and 3.05 ± 63.17, p = 0.061, respectively). LVEF, myocardial mass, stroke volume, left ventricle end-diastolic volume and end-systolic volume changed non-significantly (–0.5 ± 4.7%, –3.5 ± 13.1 g, –0.7 ± 8.6 mL, 1.9 ± 25.1 mL and 2.6 ± 16.5 mL, respectively) in the placebo group and in the ASC group (0.7 ± 8.6%, 0.9 ± 10.8 g, –0.3 ± 26.1 mL, –3.0 ± 31.5 mL and –2.7 ± 20.4 mL, respectively) from baseline to 6 months follow-up. The amount of scar tissue was unchanged in the placebo group by 0.0 ± 1.6 g, p = 1.0 and in the ASC group with –0.3 ± 2.3 g, p = 0.540. There was no difference between the groups. There was a non-significant trend toward increased myocardial perfusion but no significant changes in functional parameters or amount of scar tissue in patients treated with ASCs compared with patients allocated into the placebo group.Keywords
Funding Information
- The Faculty of Health and Medical Science Research Foundation (NA)
This publication has 27 references indexed in Scilit:
- Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled StudyStem Cells International, 2017
- Measuring myocardial perfusion: the role of PET, MRI and CTClinical Radiology, 2015
- Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)European Heart Journal, 2015
- Quantification of myocardial perfusion using cardiac magnetic resonance imaging correlates significantly to rubidium-82 positron emission tomography in patients with severe coronary artery disease: A preliminary studyEuropean Journal of Radiology, 2014
- Direct Intramyocardial Mesenchymal Stromal Cell Injections in Patients with Severe Refractory Angina: One-Year Follow-UpCell Transplantation, 2013
- Endocardial and epicardial myocardial perfusion determined by semi-quantitative and quantitative myocardial perfusion magnetic resonanceThe International Journal of Cardiovascular Imaging, 2011
- -Decay Half-Lives of Very Neutron-Rich Kr to Tc Isotopes on the Boundary of the-Process Path: An Indication of Fast-Matter FlowPhysical Review Letters, 2011
- Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarctionEuropean Journal of Heart Failure, 2008
- Effects of Transmyocardial Revascularization on Myocardial Perfusion and Systolic Function Assessed by Nuclear and Magnetic Resonance Imaging MethodsScandinavian Cardiovascular Journal, 2001
- Influence of age and hemodynamics on myocardial blood flow and flow reserve.Circulation, 1993